Nadroparin
From Wikipedia, the free encyclopedia
Nadroparin
|
|
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | ? |
ATC code | B01 |
PubChem | ? |
Chemical data | |
Formula | ? |
Mol. mass | Mean MW = 4500 Daltons |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Nadroparin is a form of low molecular weight heparin.
[edit] References
- The Merck Index, 12th Edition. 6434
[edit] External links
- http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
- http://www.mayoclinic.com/health/drug-information/DR600971
- Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology 78 (3): 136–43. doi: . PMID 17057417.